Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 18/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MAP2K2 | P36507 | 5/20 | 0.43 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.42 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7047882 | 0.93 | MAP2K1 (0.45) | MAP2K1MEN1KMT2ATDP1MAP2K2 | |
| SCHEMBL4862914 | 0.93 | MAP2K1 (0.53) | MAP2K1MEN1KMT2ATDP1MAP2K2 | |
| SCHEMBL4864348 | 0.93 | MAP2K1 (0.53) | MAP2K1MEN1KMT2ATDP1MAP2K2 | |
| SCHEMBL7050219 | 0.90 | MAP2K1 (0.42) | MAP2K1MEN1KMT2ATDP1MAP2K2 | |
| SCHEMBL7052404 | 0.87 | MAP2K1 (0.49) | MAP2K1MEN1KMT2ATDP1MAP2K2 | |
| SCHEMBL7050032 | 0.86 | MAP2K1 (0.47) | MAP2K1MAP2K2MAP2K5EIF2AK1PIM1 | |
| SCHEMBL7052711 | 0.86 | MAP2K1 (0.43) | MAP2K1MAP2K2MAP2K5EIF2AK1PIM1 | |
| SCHEMBL4862771 | 0.85 | MAP2K1 (0.50) | MAP2K1MEN1KMT2ATDP1MAP2K2 | |
| SCHEMBL4858115 | 0.85 | MAP2K1 (0.50) | MAP2K1MEN1KMT2ATDP1MAP2K2 | |
| SCHEMBL4853102 | 0.85 | MAP2K1 (0.50) | MAP2K1MEN1KMT2ATDP1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960614-B2 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| US-20040054172-A1 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054172-A1 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | CYP4X1, ALOX5, HAAO | MAP2K1 4312/4885MEN1 3335/4885KMT2A 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.